Global Footprint Sun Pharma operates more than 40 manufacturing facilities across five continents, serving customers in over 100 countries, enabling reliable, scalable supply and long-term partnerships with distributors and healthcare providers.

R&D Advantage With around 3,000 scientists and 6-8% of revenue invested in R&D, Sun Pharma can accelerate development and regulatory approvals for new generics and specialty products, enabling co-development, licensing, and faster market access for partners.

Financial Momentum The company posted strong profitability with Q4 net profit around Rs 2,714 crore and revenue near $10B, while pursuing offshore financing of $3-4B to support expansion, signaling capacity for large, multi-year contracts.

Market Leadership As the world’s fourth-largest speciality generic player and India’s market leader, Sun Pharma offers credibility and scale to win tenders and enter new geographies, complemented by a robust new product launch cadence (11 in Q4, 37 in FY26).

Pipeline Collaboration The aggressive product rollout program creates opportunities for exclusive distribution, regional licensing, and portfolio diversification with distributors and hospital networks seeking expanded generic and specialty offerings.